Vancouver, British Columbia, June 14th, 2021 BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys”), is pleased to announce today that the US Food and Drug Administration (FDA) has reviewed its Pre-IND request for a Type B review of its CoviDTH program and has determined that a Written Response is sufficient to address the Company’s questions […]
Vancouver, British Columbia and Lyon, France, June 1st, 2021, BioVaxys Technology Corp. (CSE:BIOV, FRA:5LB, US OTCQB:BVAXF) (“BioVaxys” or “the Company”) is pleased to announce that its bioproduction partner Bio Elpida of Lyon, France, has initiated construction of a new Good Manufacturing Practice (“GMP”) clean room facility needed for producing clinical supply of BVX-0918A, BioVaxys’ ovarian […]
Vancouver, British Columbia. May 24th, 2021, BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, US OTCQB:BVAXF) (“BioVaxys” or “the Company”) is pleased to announce that Charles J. Dunton, MD, has joined BioVaxys as an Advisor to help provide additional scientific support for BVX-0918A, the Company’s ovarian cancer vaccine candidate, and its planned marketing and sale of Papilocare […]
Vancouver, British Columbia, May 20th 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:BVAXF) (“BioVaxys”), a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic products, today announced the appointment of Adam Coutts, PhD, as Policy Advisor. Dr. Coutts is a Senior Research Fellow at Magdalene College, University of Cambridge and a Research […]
Vancouver, British Columbia, May 19th, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys”), the world leader in haptenized antigen vaccines for antiviral and cancer applications, is pleased to announce that it is has been uplisted from the OTC Pink Sheets to the OTCQB Venture Market in the United States. Effective today, BioVaxys shares […]
Vancouver, British Columbia, April 26th, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: BVAXF) (“BioVaxys” or “Company”) announced today that it has signed the definitive exclusive bioproduction agreement (“Agreement”) with BioElpida S.A.S. (“BioElpida”) of Lyon, France, to begin the clinical-grade bioproduction and aseptic packaging for BXV-0918A, BioVaxys’ vaccine candidate for Stage III/Stage IV ovarian […]
Cancer Vaccine Platform Patent Coverage Expanded To Now Include Over 12 Tumor Types Vancouver, British Columbia, April 29th, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:BVAXF) (“BioVaxys” or “the Company”), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it has filed with the United States Patent & […]
Vancouver, British Columbia, April 21st, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:BVAXF) (“BioVaxys”), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced that effective today it has been assigned a new US OTC trading symbol of BVAXF. This replaces the prior US OTC trading symbol of LMNGF. BioVaxys has […]
Vancouver, British Columbia, and Toronto, Ontario April 20th, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys”), the world leader in haptenized antigen vaccines for antiviral and cancers applications, announced today its sponsorship of this year’s World Ovarian Cancer Day, a major initiative of the World Ovarian Cancer Coalition (“the Coalition”), an international non-profit […]
Vancouver, British Columbia, March 31st, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys”), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it is has filed a pre-IND (Investigational New Drug) meeting request and submitted a briefing package with the US Food and Drug Administration (FDA), Center […]